@article{dayChemoradiotherapyConcurrentDurvalumab2022,
 author = {Day, Fiona and Sridharan, Swetha and Lynam, James and Gedye, Craig and Johnson, Catherine and Fraser, Allison and Thompson, Stephen R. and Michael, Michael and Leong, Trevor and Roy, Amitesh and Kumar, Mahesh and van der Westhuizen, Andre and Quah, Gaik T. and Mandaliya, Hiren and Mallesara, Girish and Sappiatzer, Joshua and Oldmeadow, Christopher and Martin, Jarad},
 file = {C\:\\Users\\Chris Oldmeadow\\Zotero\\storage\\RQJNHDB2\\Day et al. - 2022 - Chemoradiotherapy with concurrent durvalumab for t.pdf},
 issn = {1471-2407},
 journal = {BMC cancer},
 keywords = {Cancer,Clinical trial,Gastrointestinal cancer},
 langid = {english},
 month = {December},
 number = {1},
 pages = {1324},
 pmcid = {PMC9758808},
 pmid = {36528772},
 shorttitle = {Chemoradiotherapy with Concurrent Durvalumab for the Palliative Treatment of Oligometastatic Oesophageal and Gastrooesophageal Carcinoma with Dysphagia},
 title = {Chemoradiotherapy with Concurrent Durvalumab for the Palliative Treatment of Oligometastatic Oesophageal and Gastrooesophageal Carcinoma with Dysphagia: A Single Arm Phase II Clinical Trial (PALEO, Sponsored by the Australasian Gastro-Intestinal Trials Group)},
 volume = {22},
 year = {2022}
}

